Aarti Pharmalabs Limited — Q4 FY26
Aarti Pharmalabs reported Q4 FY26 standalone revenue of ₹580 crore (+9% YoY), but EBITDA fell to ₹134 crore (-5% YoY) and PAT dropped to ₹62 crore (-30% YoY), impacted by a ₹33...
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q3 FY26
FY26 EBITDA flat to marginal growth
Management expects FY26 EBITDA to be largely in line with last year with only marginal growth, revised down from earlier expectations due to Atali delays and API softness.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q3 FY26
CDMO revenue guidance for FY26 maintained
Management is confident of meeting the CDMO revenue guidance for FY26, though exceeding the target is now difficult due to project delays.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q3 FY26
Zanthin expansion mechanical completion by March 2026
The Zanthin expansion is on track for mechanical completion by end of March 2026, with incremental capacity available from Q1 FY27.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1
Q3 FY26
Atali plant resolution by Q4 FY26
Startup hiccups at Atali are expected to be resolved by end of Q4 FY26, with corrective actions in place.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1